Shionogi & Co., Ltd. (TYO:4507)

Market Cap	2.12T
Revenue (ttm)	438.30B
Net Income (ttm)	170.40B
Shares Out	850.69M
EPS (ttm)	200.31
PE Ratio	12.46
Forward PE	12.11
Dividend	58.00 (2.31%)
Ex-Dividend Date	Mar 28, 2025

Volume	673,000
Average Volume	2,362,820
Open	2,474.50
Previous Close	2,496.50
Day's Range	2,474.00 - 2,517.00
52-Week Range	1,944.66 - 2,552.50
Beta	0.10
RSI	62.26
Earnings Date	Jul 28, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,955
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4507

Financial Performance

In 2024, Shionogi &'s revenue was 438.30 billion, an increase of 0.74% compared to the previous year's 435.08 billion. Earnings were 170.40 billion, an increase of 5.17%.